DP 9244
Alternative Names: DP-9244Latest Information Update: 12 Jan 2024
At a glance
- Originator Sprint Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma; Solid tumours
Most Recent Events
- 31 Dec 2023 Deciphera Pharmaceuticals terminates its license for DP 9244 with Sprint Bioscience (Sprint Bioscience pipleline, January 2024)
- 11 Oct 2023 Pharmacodynamics data from preclinical study in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 12 Aug 2021 Preclinical trials in Malignant melanoma in USA (PO) (Sprint Biosciences pipeline, August 2021)